Lisata Therapeutics (NASDAQ:LSTA) Trading Up 2.4% – Still a Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares shot up 2.4% during mid-day trading on Wednesday . The company traded as high as $2.62 and last traded at $2.53. 264,033 shares changed hands during trading, an increase of 980% from the average session volume of 24,443 shares. The stock had previously closed at $2.47.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LSTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research report on Thursday, August 21st. Finally, Brookline Capital Management upped their price objective on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Stock Up 2.4%

The company has a market capitalization of $22.15 million, a PE ratio of -1.13 and a beta of 1.04. The business’s 50 day simple moving average is $2.45 and its 200 day simple moving average is $2.45.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $0.07 million during the quarter. On average, analysts anticipate that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Citadel Advisors LLC acquired a new position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned about 0.28% of Lisata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.94% of the stock is owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.